CA-ASM-GLOBAL
ASM Global, the world’s leading venue management company and producer of live experiences, has partnered with the Malaysian Ministry of Youth and Sports via Perbadanan Stadium Malaysia (PSM) to enhance existing operations and event activity at the Kuala Lumpur Sports City precinct, the largest sports complex in the region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220721005375/en/
The announcement is a further step forward in the Malaysian government’s ambition to see the National Sports Precinct at Bukit Jalil develop a world-class reputation as the host of leading sports, entertainment and community events. It also expands ASM Global’s footprint in Asia with the addition of an iconic sports and events precinct, including the 87,400-seat Malaysia National Stadium.
The Malaysia National Stadium is not only the largest stadium in Asia outside North Korea, it is now the largest stadium in ASM Global’s worldwide collection.
ASM Global brings its vast industry experience in redefining the guest journey, implementing the latest technology, elevating F&B offerings, and the advantage of a regionally based team together with its commercial venue know-how, wide ranging event network and technical capabilities.
ASM Global President and CEO Ron Bension said, “We’re on a robust growth curve in this part of the world. The Kuala Lumpur Sports City precinct is representative of the types of projects we’re championing that significantly enrich the venue benefits and utilize our vast international expertise and best practices.”
Chairman and Chief Executive of ASM Global Asia Pacific and Gulf Region Harvey Lister AM said the group was delighted to be partnering with the management team at the iconic Kuala Lumpur Sports City in a joint endeavor to further establish the precinct as a vibrant community and event hub for the people of Malaysia.
“We firmly believe the Malaysia National Stadium and the Axiata Arena have the potential expressed by the Malaysia Sports Ministry, and we are proud to welcome the local teams and venues into our network of venues and support the precinct in helping deliver more events for the people of Malaysia and the region,” said Lister.
ASM Global will partner with local Malaysian company Sportswork Sdn Bhd in delivering services for Kuala Lumpur Sports City.
Malaysia Sports Minister, Y.B. Dato’ Seri Ahmad Faizal bin Dato’ Azumu, said, “We see this MOU as a great opportunity for PSM and ASM Global to enhance Kuala Lumpur Sports City to a premier destination in the global sports and event industry. Both National Stadium Bukit Jalil and Axiata Arena are iconic properties owned by the Malaysian people, and we owe them a responsibility to ensure these venues make us proud.”
ABOUT ASM GLOBAL
ASM Global is the world’s leading producer of entertainment experiences. It is the global leader in venue and event strategy and management—delivering locally tailored solutions and cutting-edge technologies to achieve maximum results for venue owners. The company’s elite venue network spans five continents with a portfolio of more than 350 of the world’s most prestigious arenas, stadiums, convention and exhibition centers, and performing arts venues. Follow us on Facebook , Instagram , LinkedIn and Twitter . asmglobal.com
ASM Global’s expanding family of facilities in the Asia Pacific includes the following venues:
- Entertainment and Sports Arenas: Qudos Bank Arena, Sydney; RAC Arena, Perth; Brisbane Entertainment Centre; Newcastle Entertainment Centre; Aware Super Theatre at ICC Sydney; BCEC Great Hall, Brisbane; Cairns Arena: Bangkok Arena and EM Live Theatre, Bangkok (under development), Coca Cola Arena, Dubai; Kai Tak Indoor Arena, Hong Kong; and Jeddah Arena, Saudi Arabia (under development).
- Live Performance Theatres: Brisbane, Cairns, Darwin, Sydney, Kuala Lumpur and Bahrain.
- Convention and Exhibition Centres: Brisbane, Cairns, Darwin, Newcastle, Sydney, Christchurch, Kuala Lumpur, Shenzhen, Bahrain (under construction) and Jeddah (under development).
- Stadiums: Suncorp Stadium in Brisbane; Kai Tak Sports Park, Hong Kong (under construction); a significant ownership of VenuesLive, the operator of Stadium Australia, Sydney; CommBank Stadium, Parramatta; Optus Stadium, Perth, and service provider to WIN Stadium, Wollongong; McDonald Jones Stadium, Newcastle; Netstrata Jubilee Stadium, Sydney; and Central Coast Stadium, Gosford.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005375/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release
L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom